"Dopamine Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate dopamine receptors.
| Descriptor ID |
D018491
|
| MeSH Number(s) |
D27.505.519.625.150.151 D27.505.696.577.150.151
|
| Concept/Terms |
Dopamine Agonists- Dopamine Agonists
- Agonists, Dopamine
- Receptor Agonists, Dopamine
- Dopamine Receptor Agonist
- Agonist, Dopamine Receptor
- Receptor Agonist, Dopamine
- Dopamine Receptor Agonists
- Dopaminergic Agonists
- Agonists, Dopaminergic
- Dopaminergic Agonist
- Agonist, Dopaminergic
- Agonists, Dopamine Receptor
- Dopamine Agonist
- Agonist, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agonists".
This graph shows the total number of publications written about "Dopamine Agonists" by people in this website by year, and whether "Dopamine Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 3 | 2 | 5 |
| 2002 | 3 | 3 | 6 |
| 2003 | 3 | 2 | 5 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 3 | 4 |
| 2007 | 3 | 2 | 5 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agonists" by people in Profiles.
-
Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
-
Apomorphine is a potent inhibitor of ferroptosis independent of dopaminergic receptors. Sci Rep. 2024 02 27; 14(1):4820.
-
Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease. Exp Neurol. 2022 01; 347:113920.
-
Development of pyrimidone D1 dopamine receptor positive allosteric modulators. Bioorg Med Chem Lett. 2021 01 01; 31:127696.
-
Kidney dopamine D1-like receptors and angiotensin 1-7 interaction inhibits renal Na+ transporters. Am J Physiol Renal Physiol. 2019 10 01; 317(4):F949-F956.
-
Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations. Pediatr Neurol. 2017 Oct; 75:66-72.
-
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
-
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016 05; 30(5):428-35.
-
Dopaminergic system and dream recall: An MRI study in Parkinson's disease patients. Hum Brain Mapp. 2016 Mar; 37(3):1136-47.
-
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.